[vc_row][vc_column][vc_empty_space height=”40px”][vc_column_text css_animation=”slideInLeft” css=””]

Rheumatoid Arthritis (RA) is a chronic autoimmune disorder where the immune system mistakenly attacks healthy joint tissues, causing inflammation, pain, and eventual joint damage. It primarily affects synovial joints, leading to cartilage erosion, bone degradation, and systemic complications. It causes chronic pain, stiffness, and fatigue, limiting mobility and daily activities like walking, gripping objects, and even self-care, reducing quality of life.

JAK (Janus Kinase) signaling plays a key role in RA by mediating pro-inflammatory cytokine signals (e.g., IL-6, IFN-γ). Cytokines bind to receptors, activating JAK enzymes, which phosphorylate STAT proteins, driving inflammatory gene expression. JAK inhibitors (e.g., Upadacitinib) block this pathway, reducing inflammation and halting disease progression.

[/vc_column_text][vc_empty_space height=”70px”][/vc_column][/vc_row][vc_row type=”vc_default” bg_type=”image” parallax_style=”vcpb-default” bg_image_new=”id^299|url^https://upajak.com/wp-content/uploads/2025/05/men-run.jpg|caption^null|alt^null|title^men-run|description^null” bg_image_repeat=”no-repeat” bg_img_attach=”fixed” bg_override=”ex-full”][vc_column][vc_empty_space height=”200px”][/vc_column][vc_column][vc_empty_space height=”200px”][/vc_column][/vc_row][vc_row type=”vc_default” css_animation=”slideInUp” el_class=”mt-top”][vc_column width=”1/4″][bsf-info-box icon_type=”custom” icon_img=”id^385|url^https://upajak.com/wp-content/uploads/2025/05/upajak1.png|caption^null|alt^null|title^upajak1|description^null” img_width=”70″ icon_style=”circle” icon_color_bg=”#D5F0FF” pos=”square_box” box_bg_color=”#DCF2FF”]If your RA symptoms persist after 3 months on a TNF blocker (e.g., HUMIRA®(Adalimumab) or ENBREL®(Etanercept)), consider switching to an alternative like Upadacitinib for better relief.[/bsf-info-box][/vc_column][vc_column width=”1/4″][bsf-info-box icon_type=”custom” icon_img=”id^386|url^https://upajak.com/wp-content/uploads/2025/05/upajak2.png|caption^null|alt^null|title^upajak2|description^null” img_width=”70″ icon_style=”circle” icon_color_bg=”#D5F0FF” pos=”square_box” box_bg_color=”#DCF2FF”]In studies, Upadacitinib relieved RA joint symptoms for some in just 1 week. Most saw major improvement by 12 weeks.[/bsf-info-box][/vc_column][vc_column width=”1/4″][bsf-info-box icon_type=”custom” icon_img=”id^387|url^https://upajak.com/wp-content/uploads/2025/05/upajak3.png|caption^null|alt^null|title^upajak3|description^null” img_width=”70″ icon_style=”circle” icon_color_bg=”#D5F0FF” pos=”square_box” box_bg_color=”#DCF2FF”]Long-term studies show that many patients taking Upadacitinib maintained symptom improvement for up to 5 years, supporting its long term effectiveness and safety in enhancing quality of life for RA sufferers.[/bsf-info-box][/vc_column][vc_column width=”1/4″][bsf-info-box icon_type=”custom” icon_img=”id^388|url^https://upajak.com/wp-content/uploads/2025/05/upajak4.png|caption^null|alt^null|title^upajak4|description^null” img_width=”70″ icon_style=”circle” icon_color_bg=”#D5F0FF” pos=”square_box” box_bg_color=”#DCF2FF”]Upadacitinib stops further irreversible joint damage to prevent more progression of diseases.[/bsf-info-box][/vc_column][/vc_row]